Q3 2023 13F Holders as of 9/30/2023
-
Type / Class
-
Equity / Voting Common Shares, no par value
-
Shares outstanding
-
51.9M
-
Number of holders
-
32
-
Total 13F shares, excl. options
-
4.21M
-
Shares change
-
+756K
-
Total reported value, excl. options
-
$10.9M
-
Value change
-
+$1.92M
-
Put/Call ratio
-
0.03
-
Number of buys
-
17
-
Number of sells
-
-7
-
Price
-
$2.58
Significant Holders of DiaMedica Therapeutics Inc. - Voting Common Shares, no par value (DMAC) as of Q3 2023
39 filings reported holding DMAC - DiaMedica Therapeutics Inc. - Voting Common Shares, no par value as of Q3 2023.
DiaMedica Therapeutics Inc. - Voting Common Shares, no par value (DMAC) has 32 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 4.21M shares
of 51.9M outstanding shares and own 8.12% of the company stock.
Largest 10 shareholders include COOPERMAN LEON G (876K shares), VANGUARD GROUP INC (789K shares), Altium Capital Management LP (496K shares), PARAGON ASSOCIATES & PARAGON ASSOCIATES II JOINT VENTURE (470K shares), Bleichroeder LP (222K shares), GEODE CAPITAL MANAGEMENT, LLC (219K shares), EAM Investors, LLC (213K shares), JACOB ASSET MANAGEMENT OF NEW YORK LLC (169K shares), FIRST MANHATTAN CO. LLC. (115K shares), and Aristides Capital LLC (106K shares).
This table shows the top 32 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.